Samuel A Wells

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. doi request reprint Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update
    Samuel A Wells
    Cancer Genetics Branch, National Cancer Institute, National Institutes of Health, Building 37, Room 10106A, 37 Convent Drive, Bethesda, Maryland 20814, USA
    J Clin Endocrinol Metab 98:3149-64. 2013
  2. doi request reprint Targeting the RET pathway in thyroid cancer
    Samuel A Wells
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Clin Cancer Res 15:7119-23. 2009
  3. pmc Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial
    Samuel A Wells
    Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Building 10, Room 13N 240E MSC 1206, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Clin Oncol 30:134-41. 2012
  4. ncbi request reprint Update: the status of clinical trials with kinase inhibitors in thyroid cancer
    Samuel A Wells
    Cancer Genetics Branch S A W, National Cancer Institute, Bethesda, Maryland 20892 and Dipartimento di Medicina Molecolare e Biotecnologie Mediche M S, Universita di Napoli Federico II, 80131 Napoli, Italy
    J Clin Endocrinol Metab 99:1543-55. 2014
  5. doi request reprint Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases
    Anna Tamburrino
    Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 18:3532-40. 2012
  6. pmc The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations
    Chan Kwon Jung
    Department of Pathology C K J, Y E N, University of Pittsburgh, Pittsburgh, Pennsylvania 15261 Department of Hospital Pathology C K J, The Catholic University of Korea, Seoul 137 701, Republic of Korea and Radiation Epidemiology and Biostatistics Branches J H L, A v B, M P L, A J S, Division of Cancer Epidemiology and Genetics and Cancer Genetics Branch S A W, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
    J Clin Endocrinol Metab 99:E276-85. 2014

Collaborators

Detail Information

Publications6

  1. doi request reprint Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update
    Samuel A Wells
    Cancer Genetics Branch, National Cancer Institute, National Institutes of Health, Building 37, Room 10106A, 37 Convent Drive, Bethesda, Maryland 20814, USA
    J Clin Endocrinol Metab 98:3149-64. 2013
    ..In this manuscript, we summarize how recent discoveries have enhanced our understanding of the molecular basis of these diseases and led to improvements in the diagnosis and management of affected patients...
  2. doi request reprint Targeting the RET pathway in thyroid cancer
    Samuel A Wells
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Clin Cancer Res 15:7119-23. 2009
    ..Also, recently developed molecular therapeutics that target the RET pathway have shown activity in clinical trials of patients with advanced MTC, a disease for which there has been no effective therapy...
  3. pmc Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial
    Samuel A Wells
    Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Building 10, Room 13N 240E MSC 1206, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Clin Oncol 30:134-41. 2012
    ....
  4. ncbi request reprint Update: the status of clinical trials with kinase inhibitors in thyroid cancer
    Samuel A Wells
    Cancer Genetics Branch S A W, National Cancer Institute, Bethesda, Maryland 20892 and Dipartimento di Medicina Molecolare e Biotecnologie Mediche M S, Universita di Napoli Federico II, 80131 Napoli, Italy
    J Clin Endocrinol Metab 99:1543-55. 2014
    ....
  5. doi request reprint Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases
    Anna Tamburrino
    Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 18:3532-40. 2012
    ..Understanding the molecular pathogenesis of medullary thyroid carcinoma (MTC) is prerequisite to the design of targeted therapies for patients with advanced disease...
  6. pmc The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations
    Chan Kwon Jung
    Department of Pathology C K J, Y E N, University of Pittsburgh, Pittsburgh, Pennsylvania 15261 Department of Hospital Pathology C K J, The Catholic University of Korea, Seoul 137 701, Republic of Korea and Radiation Epidemiology and Biostatistics Branches J H L, A v B, M P L, A J S, Division of Cancer Epidemiology and Genetics and Cancer Genetics Branch S A W, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
    J Clin Endocrinol Metab 99:E276-85. 2014
    ..Thyroid cancer incidence rates in the United States and globally have increased steadily over the last 40 years, primarily due to a tripling of the incidence of papillary thyroid carcinoma (PTC)...